Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing Clinical Trials.
作者信息
Abrams-Downey Alexandra, Saabiye Joseph, Vidaurrazaga Monica
机构信息
Icahn School of Medicine at Mount Sinai, Division of Infectious Diseases, New York, NY, USA.
Icahn School of Medicine at Mount Sinai, Division of Infectious Diseases, New York, NY, USA.
出版信息
Eur Urol Focus. 2020 Sep 15;6(5):1028-1031. doi: 10.1016/j.euf.2020.05.019. Epub 2020 Jun 5.
Abstract
摘要
相似文献
1
Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing Clinical Trials.治疗新型冠状病毒肺炎的研究性疗法：正在进行的临床试验的最新情况
Eur Urol Focus. 2020 Sep 15;6(5):1028-1031. doi: 10.1016/j.euf.2020.05.019. Epub 2020 Jun 5.
2
Characteristics of the Multiplicity of Randomized Clinical Trials for Coronavirus Disease 2019 Launched During the Pandemic.在大流行期间启动的 2019 年冠状病毒病随机临床试验的多发性特征。
JAMA Netw Open. 2020 Jul 1;3(7):e2015100. doi: 10.1001/jamanetworkopen.2020.15100.
3
Treatment of SARS-CoV-2: How far have we reached?新型冠状病毒肺炎的治疗：我们已经取得了多大进展？
Drug Discov Ther. 2020 May 6;14(2):67-72. doi: 10.5582/ddt.2020.03008. Epub 2020 Apr 25.
4
Potential strategies for combating COVID-19.应对 COVID-19 的潜在策略。
Arch Virol. 2020 Nov;165(11):2419-2438. doi: 10.1007/s00705-020-04768-3. Epub 2020 Aug 10.
5
Some drugs for COVID-19.一些用于治疗新冠肺炎的药物。
Med Lett Drugs Ther. 2020 Apr 6;62(1595):49-50.
6
Race to find COVID-19 treatments accelerates.寻找新冠病毒治疗方法的竞赛加速。
Science. 2020 Mar 27;367(6485):1412-1413. doi: 10.1126/science.367.6485.1412.
7
Psychopharmacology of COVID-19.新型冠状病毒肺炎的精神药理学。
Psychosomatics. 2020 Sep-Oct;61(5):411-427. doi: 10.1016/j.psym.2020.05.006. Epub 2020 May 18.
8
Treatments for COVID-19: where are we now?2019冠状病毒病的治疗方法：我们目前处于什么阶段？
Br J Community Nurs. 2020 Aug 2;25(8):412-413. doi: 10.12968/bjcn.2020.25.8.412.
9
Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021).新冠病毒疾病药物治疗最大规模临床试验的当前进展洞察（截至2021年1月）
Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2021 Apr 23;42(1):5-18. doi: 10.2478/prilozi-2021-0001.
10
Clinical management of COVID-19.《COVID-19 的临床管理》
Indian J Med Res. 2020 May;151(5):401-410. doi: 10.4103/ijmr.IJMR_957_20.
引用本文的文献
1
Convalescent Plasma Therapy in Critically Ill COVID-19 Patients: An Open Label Trial.新冠重症患者的恢复期血浆治疗：一项开放标签试验
Oman Med J. 2021 Sep 30;36(5):e296. doi: 10.5001/omj.2021.105. eCollection 2021 Sep.
2
3
Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma.从汇集的 COVID-19 恢复期血浆中生产抗 SARS-CoV-2 静脉用免疫球蛋白。
Immunotherapy. 2021 Apr;13(5):397-407. doi: 10.2217/imt-2020-0263. Epub 2021 Feb 9.
4
COVID-19 Clinical Trials Registered Worldwide for Drug Intervention: An Overview and Characteristic Analysis.全球注册的COVID-19药物干预临床试验：概述与特征分析
Drug Des Devel Ther. 2020 Nov 19;14:5097-5108. doi: 10.2147/DDDT.S281700. eCollection 2020.
5
Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial.皮下注射托珠单抗治疗成人重症和危重症 COVID-19：一项前瞻性开放标签非对照多中心试验。
Int Immunopharmacol. 2020 Dec;89(Pt B):107102. doi: 10.1016/j.intimp.2020.107102. Epub 2020 Oct 13.
本文引用的文献
1
Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19.羟氯喹在美国 COVID-19 住院患者中的使用效果。
Med. 2020 Dec 18;1(1):114-127.e3. doi: 10.1016/j.medj.2020.06.001. Epub 2020 Jun 5.
2
Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.瑞德西韦治疗新冠病毒病-初步报告。回复。
N Engl J Med. 2020 Sep 3;383(10):994. doi: 10.1056/NEJMc2022236. Epub 2020 Jul 10.
3
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.瑞德西韦在感染 SARS-CoV-2 的恒河猴中的临床获益。
Nature. 2020 Sep;585(7824):273-276. doi: 10.1038/s41586-020-2423-5. Epub 2020 Jun 9.
4
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.瑞德西韦治疗成人重症 COVID-19 的随机、双盲、安慰剂对照、多中心临床试验。
Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29.
5
Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.羟氯喹治疗主要为轻症和中症的 2019 冠状病毒病患者：开放标签、随机对照试验。
BMJ. 2020 May 14;369:m1849. doi: 10.1136/bmj.m1849.
6
Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data.羟氯喹治疗需要吸氧的 COVID-19 肺炎患者的临床疗效：利用常规护理数据进行的观察性对比研究。
BMJ. 2020 May 14;369:m1844. doi: 10.1136/bmj.m1844.
7
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.纽约州 COVID-19 患者住院死亡率与羟氯喹或阿奇霉素治疗的关联。
JAMA. 2020 Jun 23;323(24):2493-2502. doi: 10.1001/jama.2020.8630.
8
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.羟氯喹治疗 COVID-19 住院患者的观察性研究。
N Engl J Med. 2020 Jun 18;382(25):2411-2418. doi: 10.1056/NEJMoa2012410. Epub 2020 May 7.
9
Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir.瑞德西韦抑制 SARS-CoV-2 的 RNA 依赖性 RNA 聚合酶的结构基础。
Science. 2020 Jun 26;368(6498):1499-1504. doi: 10.1126/science.abc1560. Epub 2020 May 1.
10
Testing an Old Therapy Against a New Disease: Convalescent Plasma for COVID-19.用一种旧疗法对抗一种新疾病：用于治疗新冠肺炎的康复期血浆
JAMA. 2020 Jun 2;323(21):2114-2117. doi: 10.1001/jama.2020.7456.
Zotero 插件